The EGFR and MET activation and the downstream of EGFR and MET signaling pathways, such as p-AKT, p-p38, p-STAT3 and p-p65 in TMZ-resistant glioma cells, were also mitigated by BIP-MPC-NP, as expected. The gene discussed is EGFR; the disease is central nervous system cancer.